Identifying Drug Prescription in Newly Diagnosed Hypertension Patients in India

Thomas Alexander, Jagdish S. Hiremath, Jitendra P. S. Swahney, Subhash Chandra, Peeyush Jain, Praveen Chandra, Nakul Sinha, T. Sashikanth, Yugandhar Bachhu, Anil Balachandran, Pathiyil Balagopalan Jayagopal, T. Govindan Unni, Tiny Nair, Kumaresan Kannan, Dorairaj Prabhakar, M. Chenniappan, Ajay U. Mahajan, Rajiv D. Karnik, Chandrashekhar K. Ponde, Prashant AdvaniIdris Ahmed Khan, Brij Mohan Goyal, P. R. Vaidyanathan, Hiren Prajapati, Willem J. Verberk*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

This study evaluated initial antihypertensive drug prescription patterns in Indian healthcare settings. An observational, cross-sectional, prospective prescription registry analyzed prescriptions for 4723 newly diagnosed hypertension patients. Additionally, it investigated the extent to which physicians adhered to either European or Indian hypertension guidelines. Angiotensin receptor blockers (ARBs) were the most commonly prescribed drugs, given to 79% of patients, followed by calcium channel blockers (CCBs) at 55%. Diuretics and beta-blockers (BBs) were prescribed to 27% and 17% of patients, respectively. Monotherapy was administered to 35% of patients, while combination therapies were more prevalent, with dual therapy at 51% and regimens involving three or more drugs prescribed to 14%. Among multi-drug treatments (n = 3082, 65%), 98% received fixed-dose combination tablets. The most common combinations were ARB + CCB (26%), ARB + diuretic (12%), and ARB + CCB + diuretic (8%). Key predictors for an increasing number of prescribed drugs included statin use/dyslipidemia, age, blood pressure level, and diabetes. Non-adherence to hypertension guidelines was evident as 1364 patients classified from moderate to very high risk received monotherapy. Of these, 496 patients had grade 2 or 3 hypertension. Additionally, 88 patients received the undesirable combination of ACEi + ARB, and 267 (15.9%) type 2 diabetes mellitus (T2DM) patients did not receive RAS-blockers (146 on monotherapy). The findings reveal a trend toward utilizing ARBs, CCBs, and combination tablets, indicating improved adherence to guidelines. However, a significant number of patients did not receive appropriate treatment, highlighting areas for improvement in prescription practices.
Original languageEnglish
Article numbere14963
Number of pages9
JournalJournal of Clinical Hypertension
Volume27
Issue number1
DOIs
Publication statusPublished - 1 Jan 2025

Keywords

  • antihypertensive therapy
  • clinical management of high blood pressure (HBP)
  • clinical pharmacology
  • combination therapy
  • epidemiology
  • RISK-FACTORS
  • TASK-FORCE
  • MANAGEMENT
  • TELMISARTAN
  • PREVENTION
  • GUIDELINES
  • AMLODIPINE
  • ADHERENCE
  • DISEASES

Fingerprint

Dive into the research topics of 'Identifying Drug Prescription in Newly Diagnosed Hypertension Patients in India'. Together they form a unique fingerprint.

Cite this